Empagliflozin Perception Mapping Survey
Abstract
Background: Heart failure (HF) is a frequent yet often underdiagnosed comorbidity among individuals with type 2 diabetes mellitus (T2DM). Sodium-glucose cotransporter-2 (SGLT2) inhibitors, particularly empagliflozin, are known to provide significant cardiovascular and renal benefits and are endorsed by international guidelines. However, real-world gaps in adoption persist, influenced by diagnostic challenges, cost considerations, and clinician familiarity. This survey assessed physician perceptions and prescribing practices regarding empagliflozin across diverse T2DM patient profiles in India. Methods: A cross-sectional, questionnaire-based survey was conducted using a voluntary convenience sampling approach among physicians from various specialities managing T2DM. As the study involved anonymized physician responses without patient-level data, ethical approval was not applicable. The survey captured information on demographic characteristics, heart failure risk assessment, SGLT2 inhibitor prescribing patterns, perceived cardio-renal benefits, and perceived barriers. Data were analyzed descriptively and summarized as frequencies and proportions. Results: Most respondents acknowledged that HF remains underdiagnosed in T2DM and recognized the role of empagliflozin in patients with cardiovascular and renal comorbidities. Physicians reported frequent use of empagliflozin in T2DM with multiple cardiovascular risk factors, established atherosclerotic cardiovascular disease…
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.